Kornimate/medical-research-clean huggingface dataset:
a study to investigate the effect of food on oral lbh589 absorption in patients with advanced solid tumors

Conditions: Cancer

Summary: the primary purpose of this study is to evaluate the effect of food on oral lbh589 in adult patients with advanced solid tumors. this study will also evaluate the safety and efficacy of lbh589 in adult patients with advanced solid tumors


Eligibility criteria:
inclusion criteria: * patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists * age ≥ 18 years old * patients must have adequate laboratory values * eastern cooperative oncology group (ecog) performance status ≤ 2 * ability to swallow capsules or tablets exclusion criteria: * patients with active central nervous system (cns) disease or brain metastases except those who have been previously treated and have been stable for at least 3 months. * patients with a second primary malignancy that is currently clinically significant or requiring active intervention * impaired heart function or clinically significant heart disease * impairment of gastrointestinal (gi) function, or gi disease that may significantly alter the absorption of lbh589 * ongoing diarrhea * liver or renal disease with impaired hepatic or renal functions * concomitant use of any anti-cancer therapy or certain drugs * female patients who are pregnant or breast feeding * patients not willing to use an effective method of birth control other protocol-defined inclusion/exclusion criteria may apply

Keywords: cancer solid tumor food effect hdac inhibitor oral lbh589
evaluation of venous thromboembolism (vte) prophylaxis in medically ill patients

Conditions: Venous Thromboembolism

Summary: vte prophylaxis is not as routinely employed in medically ill patients as compared to surgical patients. this retrospective chart review project will evaluate the effectiveness of vte prophylaxis in medically ill patients at the university of utah hospitals and clinics compared to current literature. the study will ultimately serve as a quality improvement project to help improve patient care.


Eligibility criteria:
inclusion criteria: * hospitalized at the university of utah on one our medical services. exclusion criteria: * patients received therapeutic anticoagulation.

Keywords: venous thromboembolism prevention quality improvement education compliance with vte prophylaxis
individualized dose escalation of 5-fu for gastrointestinal cancer

Conditions: Colorectal Cancer; Esophagus Cancer; Appendix Cancer; Small Bowel Cancer; Ampullary Cancer

Summary: this is a single-arm clinical trial to evaluate the feasibility of a chemotherapy regimen using adaptive, individualized dose escalation of 5-fu chemotherapy for patients who have good tolerance of the initial dose. study participants will also receive oxaliplatin chemotherapy together with 5-fu, at standard doses. the goal of the study is to examine the feasibility and effectiveness of this approach, using individualized dose escalation of 5-fu in patients who do not have serious side effects at lower doses.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of metastatic or locally advanced/inoperable colorectal cancer or non-colorectal gastrointestinal cancer (including cancers of the stomach, esophagus, appendix, small bowel, and ampulla) * clinically appropriate staging imaging of the chest, abdomen, and pelvis performed within 30 days prior to registration * ecog performance status: 0-1 exclusion criteria: * any prior receipt of oxaliplatin or fluoropyrimidine chemotherapy (other than radiation-sensitizing fluoropyrimidine chemotherapy) * prior receipt of systemic chemotherapy in the 6 months prior to day 1 of cycle 1 of fox (other than radiation-sensitizing chemotherapy) * known mismatch repair deficiency or microsatellite instability-high disease * known dihydropyrimidine dehydrogenase (dpd) deficiency, as identified by clinically indicated screening * any confirmed second malignancy that is likely to require systemic therapy during the course of the six-month study period, in the opinion of the enrolling investigator * any of the following baseline laboratory abnormalities: * absolute neutrophil count (anc) \< 2,500/mm3 * platelet count \< 100,000/mm3 * hemoglobin \< 9 g/dl * creatinine \> 1.5 x uln * total bilirubin \> 1.5 x uln * ast/alt \> 5 x uln * patients who are unable to provide informed consent * patients who are pregnant or breastfeeding * patients who are incarcerated, homeless, or have active substance use disorders
treatment of obstructive sleep apnea in chronic kidney disease

Conditions: Sleep Apnea, Obstructive; Renal Insufficiency, Chronic

Summary: this study is being conducted to determine whether treatment of obstructive sleep apnea (osa) in patients with chronic kidney disease (ckd) improves kidney function. half of the participants will receive continuous positive airway pressure (cpap) treatment for their osa in addition to their regular ckd treatment, while the other half will only receive their regular ckd treatment.

obstructive sleep apnea (osa) and associated hypoxemia during sleep have been associated with a decline in kidney function. the abnormalities in kidney function associated with osa have been improved by treatment of osa with continuous positive airway pressure (cpap), which is a common and effective therapy for osa. up to now, clinical research on the impact of osa on kidney function has been performed on patients without ckd. this study will examine the impact of cpap therapy on kidney function in patients with ckd. ckd patients with osa and nocturnal hypoxemia will be randomized into one of two groups where half will receive treatment of their osa with cpap and the other half will not. all participants will have kidney function monitored every 3 months for a year by measurement of serum creatinine and proteinuria. the change in estimated glomerular filtration rate (egfr) and proteinuria between the two groups will be assessed to determine whether treatment of osa improves kidney function in patients with ckd.

Eligibility criteria:
inclusion criteria: * ckd stage 3 or 4 * osa (rdi\>5) and nocturnal hypoxemia (sao2 \ 12% of night) exclusion criteria: * failure to meet inclusion criteria * current therapy with cpap or supplemental oxygen * severe daytime sleepiness reflected by an epworth sleepiness score \>15 * any driver who holds a commercial drivers' license or who reports a recent history (past 6 months) of a road traffic accident * severe nocturnal hypoxemia reflected by mean sao2 \<80% during level 3 sleep testing * daytime hypoxemia reflected by partial pressure of oxygen in arterial blood (pao2) less than 60 millimetres of mercury (mmhg) during wakefulness * hypoventilation reflected by partial pressure of carbon dioxide in arterial blood (paco2) greater than 45 millimetres of mercury (mmhg) during wakefulness * central sleep apnea that accounts for \>50% of the estimated rdi * unable to provide informed consent
non-operative treatment in sweden of proximal humeral fractures

Conditions: Proximal Humeral Fracture

Summary: proximal humeral fractures are common especially in the elderly population. the majority of these fractures are minimally displaced and may be treated non-operatively. there is however a controversy about which fractures that need surgery and randomised trials have not been able to show a clinically important advantage in patient reported outcome measures for those operated. the trend is therefore that also displaced and comminute fractures are treated non-operatively. there is however very little scientific support for how the non-operative treatment should be designed and performed. therefore this prospective multicenter study is aiming at investigating the benefit of a four week immobilisation orthosis as compared to early range of motion exercises for those patients not assigned for surgery one week after the trauma.


Eligibility criteria:
inclusion criteria: * a proximal humeral fracture verified on radiology no older than 7-10 days. exclusion criteria: * surgically treated proximal humeral fracture * fracture only involving the greater tuberosity * previous surgery in the fractured shoulder * ongoing malignancy in the fractured shoulder * neurologic disease * radiating pain from the neck in the affected arm * associated vascular or nerve injuries * dementia * alcohol abuse * unwilling to participate in the trial

Keywords: non-operative treatment, orthosis, healing, rehabilitation
mortality due to covid-19 in the covid-agebru study

Conditions: Covid19; Old Age; Debility; Morbidity, Multiple

Summary: the covid-age brugmann study aims to identify the clinical predictors of mortality risk in older patients admitted to an acute care unit due to covid-19

the covid-19 disease has been shown to be associated to higher mortality risk and health adverse consequences. despite of the fact that the sar-cov2 virus has been shown that affects every populations, the negative impact is higher in older people, pointing this population as the most severely affected. the covid-age brugmann study aims to identify if comorbidity, geriatric syndromes, and health issues at admission are associated to mortality risk in older patients admitted to an acute care unit due to covid-19

Eligibility criteria:
inclusion criteria: * patients aged 70 and older * patients admitted to an acute care geriatric unit due to covid-19 * patients with covid-19 by pcr, serology or ct scan suggestive of this disease exclusion criteria: * no other demographic or clinical exclusion criteria will be applied
safety and efficacy study in adult subjects with acute migraines

Conditions: Migraine, With or Without Aura

Summary: the purpose of this study is to compare the efficacy of bhv-3000 (rimegepant) versus placebo in subjects with acute migraines


Eligibility criteria:
key inclusion criteria: 1. patient has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the international classification of headache disorder, 3rd edition, beta version\[1\] including the following: * not more than 8 attacks of moderate or severe intensity per month within last 3 months * consistent migraine headaches of at least 2 migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the screening visit and maintains this requirement during the screening period 2. less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the screening visit and maintains this requirement during the screening period 3. patients on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to study entry. 4. patients with contraindications for use of triptans may be included provided they meet all other study entry criteria. key exclusion criteria: 1. patient history of hiv disease 2. patient history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. patients with myocardial infarction (mi), acute coronary syndrome (acs),percutaneous coronary intervention (pci), cardiac surgery, stroke or transient ischemic attack (tia) during the 6 months prior to screening. 3. uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however patients can be included who have stable hypertension and/or diabetes for 3 months prior to being enrolled) 4. patient has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (eg, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the investigator's opinion, might interfere with study assessments 5. patient has a history of gastric, or small intestinal surgery, or has a disease that causes mal-absorption 6. the patient has a history or current evidence of any significant and/or unstable medical conditions (eg, history of congenital heart disease or arrhythmia, known suspected infection, hepatitis b or c, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (ae) or interfere with assessments of safety or efficacy during the course of the trial 7. history of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or patients who have met dsm-v criteria for any significant substance use disorder within the past 12 months from the date of the screening visit.
periodontal disease prevention study

Conditions: Periodontitis

Summary: this study is one component of a program to improve the maintenance of good dental health and the prevention of disease by use of risk stratification methods to efficiently guide increased preventive services to adult dental patients who are at increased risk for the major dental diseases, caries and adult periodontitis. the investigators will use a retrospective cohort model to analyze a large dental claims database to determine if the frequency of preventive services influenced the periodontal disease outcomes and to determine if periodontal risk assessment information can be used to stratify dental patients into "high risk" and "low risk" categories that influence the effect of preventive services on periodontitis outcomes. primary objective to evaluate whether dental patients who are classified as "low risk" for periodontal disease progression, based on history of periodontitis (claims history), smoking, diabetes, and il-1 genetic variations, have different primary and secondary endpoints if they had two dental cleanings per year compared to one cleaning per year. secondary objectives to evaluate whether dental patients who are classified as "high risk" for periodontal disease progression, based on a history of periodontitis, smoking, diabetes, and il-1 genetic variations, have different primary and secondary endpoints if they had two dental cleanings per year compared to one cleaning per year. to evaluate whether dental patients who have had one dental cleaning per year have different primary and secondary endpoints if they are classified as "low risk" for periodontal disease compared to patients who are classified as "high risk." to evaluate whether dental patients who have had two dental cleaning per year have different primary and secondary endpoints if they are classified as "low risk" for periodontal disease compared to patients who are classified as "high risk."


Eligibility criteria:
inclusion criteria: * study may include all participants who are 34-55 years old in 1992 (48-68 years old in 2010) and who have at least a 15-year dental claim history with delta dental. exclusion criteria: * organ transplant recipients are excluded.

Keywords: periodontitis
fexofenadine in pruritic skin disease

Conditions: Pruritus

Summary: primary objective: * to compare the efficacy and safety profile of fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease secondary objective: * to evaluate patient's satisfaction of allegra treatment


Eligibility criteria:
the following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. this information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional. main criteria are listed hereafter: inclusion criteria: * all patients diagnosed with atopic dermatitis, contact dermatitis exclusion criteria: * other skin disease except atopic dermatitis, contact dermatitis. * subjects taken steroid within 4 weeks and antihistamine within 1 week before screening day. * pruritus localized only head and face * subjects with severe hepatic, renal, heart dysfunction. * subjects with history of alcohol and drug abuse. * pregnant and lactating women.
arterial embolization for the treatment of bone metastases: prospective observational study

Conditions: Bone Metastases

Summary: to date, arterial embolization constitutes one of the most popular methods in minimally invasive treatment of bone metastases, allowing good results in terms of pain reduction, local control of disease and reduction of peri-operative bleeding, with low invasiveness.


Eligibility criteria:
inclusion criteria: * patients of either sex of age or older who are candidates for embolization therapy * life expectancy \> 3 months * single metastatic or oligometastatic. * plurimetastatic if a particular site is causing painful symptoms or at risk for pathologic rupture exclusion criteria: * patients with life expectancy \<3 months or severe functional status impairment (asa 4) * patients with hypovascular metastasis documented by angiography or mri perfusion study with mdc. * patients with coagulation deficiency or plateletopenic patients. * patients with documented active infection.

Keywords: arterial embolization
co-treatment with pegvisomant and a somatostatin analogue (sa) in sa-responsive acromegalic patients

Conditions: Acromegaly; Insulin Resistance; Impaired Glucose Tolerance

Summary: the purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on sa monotherapy, with pegvisomant and sa will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to sa mono therapy. second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.


Eligibility criteria:
inclusion criteria: * age \> 18 * diagnosed with acromegaly * safe anticonceptive for fertile women * well controlled on somatostatin analog (a serum igf-i within normal range a nadir gh \< 0.5 µg/l.) exclusion criteria: * pregnancy * liver disease * diabetes mellitus type i * magnetic or electronic implants

Keywords: acromegaly insulin sensitivity glucose tolerance body composition growth hormone
safety and performance study of the nyxoah sat system for treating osa

Conditions: Obstructive Sleep Apnea

Summary: a prospective open-label, single treatment study to assess the safety and the performance of the nyxoah sat system for the treatment of obstructive sleep apnea


Eligibility criteria:
inclusion criteria: * diagnosed with moderate to severe obstructive sleep apnea * have failed or have not tolerated cpap treatment * willing and capable of providing informed consent * willing and capable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires exclusion criteria: * bmi limits * subjects with complete concentric collapse at the soft palate level per endoscopy
steroid-antiviral treatment in rehabilitation of facial palsy

Conditions: Facial Palsy

Summary: the purpose of this study is to assess the efficacy of antiviral medicine (acyclovir) in recovery of complete facial palsy. fifty patients (males and females) with acute facial palsy within the first 3 days of onset with age ranged from 15-60 years old. each patient was submitted to the following clinical evaluation using house and brackmann 6 facial function scoring system and synnybrook grading system. neurophysiological assessment of facial nerve and muscles was done before and after the end of treatment, then after the end of first and second month of treatment. emg was done for facial muscles of both sides beside measuring facial nerve excitability to determine the excitation threshold by recording the minimum electrical stimulus required to produce visible muscle contraction. a difference greater than 3.5 ma between the affected and unaffected side is considered significant in terms of poor prognosis. nerve conduction study of facial nerves of both sides using concentric needle electrode. trigeminal blink reflex for both sides of the face. facial functional recovery was defined as "good" or "complete" using the same criteria used in the 2001 practice guideline. an outcome of grade i or ii was considered a good recovery using the house and brackmann 6 facial function scoring system

the purpose of this study is to assess the efficacy of antiviral medicine (acyclovir) in recovery of complete facial palsy. fifty patients (males and females) with acute facial palsy within the first 3 days of onset with age ranged from 15-60 years old. each patient was submitted to the following clinical evaluation using house and brackmann 6 facial function scoring system and synnybrook grading system. neurophysiological assessment of facial nerve and muscle was done before and after the end of treatment, then after the end of first and second month of treatment. emg was done for facial muscles of both sides beside measuring facial nerve excitability to determine the excitation threshold by recording the minimum electrical stimulus required to produce visible muscle contraction. a difference greater than 3.5 ma between the affected and unaffected side is considered significant in terms of poor prognosis. nerve conduction study of facial nerves of both sides using concentric needle electrode. trigeminal blink reflex for both sides of the face. facial functional recovery was defined as "good" or "complete" using the same criteria used in the 2001 practice guideline. an outcome of grade i or ii was considered a good recovery using the house and brackmann 6 facial function scoring system

Eligibility criteria:
inclusion criteria: * acute onset facial palsy within the first three days of onset. age ranged from 15-60 years old exclusion criteria: * patients with brittle diabetes mellitus, morbid obesity, renal or liver impairment, osteopenia, prior history of steroid intolerance.

Keywords: facial palsy (acute), acyclovir, prednisolone